Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder

Negar Molazadeh, Angeliki G. Filippatou, Eleni S. Vasileiou, Michael Levy, Elias S. Sotirchos

Research output: Contribution to journalReview articlepeer-review

Abstract

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and aquaporin-4 IgG seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) are generally considered to be relapsing disorders, without clinical progression or subclinical disease activity outside of clinical relapses, in contrast to multiple sclerosis (MS). With advances in the diagnosis and treatment of these conditions, prolonged periods of remission without relapses can be achieved, and the question of whether progressive disease courses can occur has re-emerged. In this review, we focus on studies exploring evidence for and against relapse-independent clinical progression and/or subclinical disease activity in patients with MOGAD and AQP4-IgG+ NMOSD.

Original languageEnglish (US)
Article number577702
JournalJournal of Neuroimmunology
Volume360
DOIs
StatePublished - Nov 15 2021
Externally publishedYes

Keywords

  • Magnetic resonance imaging
  • Myelin oligodendrocyte glycoprotein
  • Neuromyelitis optica
  • Optical coherence tomography
  • Progressive
  • Subclinical

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder'. Together they form a unique fingerprint.

Cite this